Harpoon Therapeutics

$16.14
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.14 (-0.86%) As of 10:13 AM EDT today
-$0.14 (-0.86%) Today

Why Robinhood?

You can buy or sell HARP and other stocks, options, ETFs, and crypto commission-free!

About HARP

Harpoon Therapeutics, Inc. Common Stock, also called Harpoon Therapeutics, is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. Read More It offers Tri-specific T cell Activating Construct (TriTACs) that focuses on the treatment of solid tumors and hematologic malignancies. The company founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Employees
45
Headquarters
South San Francisco, California
Founded
2015
Market Cap
399.90M
Price-Earnings Ratio
Dividend Yield
Average Volume
84.12K
High Today
$16.10
Low Today
$15.85
Open Price
$15.87
Volume
2.79K
52 Week High
$17.85
52 Week Low
$9.07

Collections

HARP Earnings

-$8.15
-$5.58
-$3.01
-$0.44
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 4, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.